Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer

2020 Year in Review - Breast Cancer —January 25, 2021

Categories:

Breast Cancer

The majority of patients with metastatic breast cancer receiving treatment with CDK4/6 inhibitors had progression-free survival, behaving similarly when used as first-line therapy or after adjuvant hormonal therapy.

Silvia Comis, MD, Senior Medical Director, Oncology-Therapeutic Science and Strategy Unit, IQVIA, Milan, Italy, and colleagues used US open health claims and prescription data to examine the pattern of behavior of CDK4/6 inhibitor combinations as first-line therapy or following adjuvant hormonal therapy in adult females with de novo metastatic breast cancer.

The researchers examined metastatic breast cancer between 2015 and 2019, in adult female patients aged >18 years. Based on their first treatment, women were classified into 3 groups (group 1, hormonal; group 2, CDK4/6 inhibitor combinations; and group 3, everolimus combination).

The percentage of patients who switched to next therapy was 3.2% (1200 patients) of the 37,351 patients receiving CDK4/6 inhibitors as first-line therapy or following adjuvant hormonal therapy for advanced or metastatic diseases. For the majority of patients, in 87% of cases, changing therapy occurred within a 2-year period, and those patients who continued with first-line therapy did so for an extended period of time.

Compared with the overall CDK4/6 inhibitor population in groups 1 and 2, no statistically significant difference was apparent in the treatment pattern. However, within the first year of treatment, 90% of patients in group 3 compared with the overall patient population receiving CDK4/6 inhibitors switched to chemotherapy (P = .02).

A detailed analysis found that the overwhelming majority (90%) of patients receiving CDK4/6 inhibitors remained on therapy for approximately 1 year, with a small percentage of patients (2%) extending treatment to between 2 and 4.5 years.

The researchers concluded that for the period analyzed, 95% of patients receiving CDK4/6 inhibitors had progression-free survival. Overall, when used as first-line therapy or following adjuvant hormonal therapy, patients receiving CDK4/6 inhibitors had comparable patterns of behavior.

Source: Comis S, Kandasamy T, Perrin AJ, et al. A retrospective analysis of CDK4/6 inhibitors among adult female patients with metastatic breast cancer. J Clin Oncol. 2020;38(15_suppl). Abstract e13028.

Related Articles
Key Breast Cancer Abstracts in 2023 and Innovations in Ovarian Function Suppression:
Matteo Lambertini, MD, PhD, Erica Stringer-Reasor, MD, Director, Sara M. Tolaney, MD, MPH
|
Video Library
Please join Sara Tolaney, MD, MPH, Dana-Farber Cancer Center, Boston, MA; Erica Stringer-Reasor, MD, University of Alabama, Birmingham; and Matteo Lambertini, MD, PhD, University of Genoa, Italy, as they provide expert commentary on key breast cancer abstracts presented at the 2023 ASCO Annual Meetings that will impact young women with ER+/HER2- breast cancer.
Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence
Video Library
The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.
Improving Adherence to Oral Oncolytics in Breast Cancer: The Pivotal Role of Nurse Navigators
September 2022 Vol 13, No 9
Oral oncolytic drugs have a multitude of benefits for patients, including ease of use, improved quality of life, fewer clinic visits, and no need for IV therapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country